{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:28:15Z","timestamp":1784734095597,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.ygyno.2013.05.006","type":"journal-article","created":{"date-parts":[[2013,5,11]],"date-time":"2013-05-11T09:16:03Z","timestamp":1368263763000},"page":"284-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Optimal (\u22641cm) but visible residual disease: Is extensive debulking warranted?"],"prefix":"10.1016","volume":"130","author":[{"given":"J.N.","family":"Barlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.C.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.J.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"M.M.","family":"Leitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.R.","family":"Abu-Rustum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.R.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.05.006_bb0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0015","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0020","first-page":"131","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian cancer","volume":"42","author":"Griffiths","year":"1978","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/gyno.1998.4955","article-title":"Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study","volume":"69","author":"Eisenkop","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0030","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0035","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0040","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0045","series-title":"Intestinal dysfunction and obstruction","author":"Mercadante","year":"2009"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0050","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2012.04.014","article-title":"Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer","volume":"126","author":"Tanner","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ygyno.2009.11.022","article-title":"The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum","volume":"116","author":"Zivanovic","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ygyno.2012.02.024","article-title":"Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining \u2018optimal\u2019 residual disease","volume":"125","author":"Chang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0070","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","article-title":"Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer","volume":"121","author":"Harter","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0075","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ygyno.2006.06.028","article-title":"The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC\u2013IV epithelial ovarian cancer","volume":"103","author":"Eisenhauer","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0080","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1006\/gyno.2001.6313","article-title":"Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with \u201cbiological aggressiveness\u201d and survival?","volume":"82","author":"Eisenkop","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0085","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","article-title":"Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study","volume":"90","author":"Eisenkop","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.05.006_bb0090","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ygyno.2011.04.041","article-title":"The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study","volume":"122","author":"Hamilton","year":"2011","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813007397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813007397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T02:55:00Z","timestamp":1539658500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813007397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0090825813007397"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal (\u22641cm) but visible residual disease: Is extensive debulking warranted?","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}